Led · Series B · Jun 2026

Connie Health is an AI-native Medicare navigation platform that combines proprietary technology with a network of local trusted agents to help seniors find and enroll in appropriate Medicare coverage. The company powers agent workflows and consumer guidance with AI and intelligent automation and positions itself as a strategic partner to Accountable Care Organizations, health systems, and risk-bearing providers. Connie recently completed its 10th acquisition, integrating Clearlink's Medicare business, and announced a $40 million Series B, bringing total funding to date to $85 million. It plans to use capital to expand its agent network, pursue additional M&A, advance its AI-driven platform, and deepen integrations with value-based care partners. Connie is headquartered in Boston and emphasizes preserving local, human-centered support while scaling through technology.

Led · Series B · Jan 2026

AnswersNow is a Richmond-based health-tech company that offers personalized, virtual applied behavioral analysis (ABA) therapy to families of children with autism. Its AI-driven platform creates individualized learning modules that adapt to each child’s interests, aiming to raise the immediacy, accessibility, and quality of care. The service is already available as in-network coverage with multiple commercial insurers and Medicaid across several states. Led by CEO Jeff Beck, the company positions itself as an affordable, scalable alternative to traditional in-person ABA therapy. With the new capital, AnswersNow plans to enhance its technology stack, expand its clinical and operational team, and deepen its AI capabilities to drive further personalization and efficiency. Prior to the latest round, the startup had attracted backing from Left Lane Capital and Owl Ventures, although earlier funding amounts were not disclosed.

Led · Series C · Sep 2025

Diana Health partners with hospitals to design and operate women's health and maternity programs that center midwives (CNMs) alongside OB‑GYNs and integrated mental health and wellness professionals. Its core offering combines team‑based clinical care, evidence‑based protocols that reserve interventions for when they are needed, and practical digital tools for education, virtual visits and care planning. The company currently operates nine locations across Tennessee, Florida and Texas and cares for over 80,000 women on an annualized basis. The $55 million Series C will fund expansion of its physical footprint, deepen integrated clinical programming, and enhance its digital platform to improve clinical outcomes and patient experience. Diana Health positions its model as a solution to the U.S. maternal health crisis by reducing unnecessary procedures and strengthening hospital service sustainability. The company has raised $101 million in capital and is backed by investors including HealthQuest Capital, Norwest Venture Partners, .406 Ventures, LRVHealth and AlleyCorp. Diana Health is a network of modern women’s health practices that partners with hospital and health system leadership to redesign labor and delivery and other women’s health programs. Its model delivers a tech-enabled, holistic care experience through integrated teams of Certified Nurse Midwives, OB/GYNs, mental health and wellness providers. Led by CEO Kate Condliffe, the company currently operates three sites in Tennessee in partnership with HCA TriStar StoneCrest Medical Center, HCA TriStar NorthCrest Medical Center and Cookeville Regional Medical Center. Diana Health plans to bring its care model to new communities across the U.S., expand its digital platform and broaden program offerings. The company will open three new sites in Florida in the next six months. Financially, Diana Health completed a $34M Series B that brought total funding to $46M. Diana Health partners with leading health systems to redesign maternity and women’s health service lines by combining integrated care teams, a digital platform, and clinical redesign of labor and delivery. The company delivers an evidence-based, individualized maternal care program intended to improve outcomes, enhance patient and clinician experience, and control costs. Diana works directly with hospital leadership to implement end-to-end prenatal and postpartum solutions and to build trusting relationships with women and families. It plans to open its first physical location and launch its first maternal care program with TriStar StoneCrest Medical Center (part of HCA Healthcare) in Smyrna, TN in the coming weeks. The company announced an $11 million Series A to fund initial site launches in 2022, expand its technology platform, and position it for rapid growth in 2023 and beyond. Diana frames its model as addressing gaps in patient experience amid rising maternal morbidity and an anticipated OB/GYN shortage.

Led · Series B · May 2025

Alpheus Medical develops a proprietary sonodynamic therapy platform that pairs Low‑Intensity Diffuse Ultrasound (LIDU™) with oral 5‑ALA, a tumor‑selective sensitizer, to deliver non‑thermal, tumor‑targeted treatment. The therapy is designed to be performed in an outpatient setting and to selectively destroy cancer cells across a brain hemisphere without the need for imaging or sedation. Early results from two studies in newly diagnosed and recurrent glioblastoma patients have shown promise. The company collaborates with global neuro‑oncology leaders and is supported by healthcare investors and nonprofit venture vehicles focused on cancer. Recent financing will fund a randomized Phase 2B controlled trial evaluating SDT’s efficacy in newly diagnosed glioblastoma. Alpheus is based in Chanhassen, Minnesota. Alpheus Medical is developing a non-invasive sonodynamic therapy (SDT) drug-device combination that uses a sonosensitizer activated by low-intensity ultrasound to selectively kill cancer cells. The lead product is designed for outpatient, repeatable whole-hemisphere treatment of recurrent high-grade gliomas, including rGBM, and eliminates the requirement for concomitant imaging. The therapy aims to address the heterogeneous and diffuse nature of glioblastoma by treating both the primary tumor site and diseased tissue throughout the hemisphere. The company reports the therapy is in early clinical stage use and is not yet commercially available. Alpheus has support from the American Cancer Society and the National Brain Tumor Society and is based in Oakdale, Minn. The recently closed financing will be used to advance a multi-site first-in-human trial evaluating safety, feasibility, and molecular and clinical effects.

Led · Equity · Apr 2025

hellocare.ai offers a unified, enterprise-ready virtual care platform that combines hardware, software, AI, and an EHR integration engine to deliver AI-Assisted Virtual Nursing, Virtual Sitting, Virtual Consultation, Ambient Documentation, digital whiteboards, patient engagement, Hospital-at-Home, RPM, and Digital Clinic. The company says its end-to-end, in-house technology stack enables rapid customization and integration for health systems. hellocare.ai is already deployed across 70+ health systems and is being rolled out enterprise-wide at AdventHealth across more than 50 hospitals and over 13,000 patient rooms. Bon Secours Mercy Health and UCHealth both participate as investors and customers, illustrating alignment between product roadmap and provider needs. The company plans to use new funding to scale rapidly, deepen its AI capabilities, and expand deployments with leading health systems. Headquartered in Clearwater, Florida, hellocare.ai positions itself as a replacement for fragmented point solutions by delivering measurable ROI and operational impact.